TGA greenlights second daily GLP-1 pill

5 minute read


Orforglipron is the first small-molecule, non-peptide GLP-1 receptor agonist of its kind and is expected to be available to patients within days. See how much it is expected to cost.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×